Value of PET-CT in Radiation Treatment Planning for Patients With Esophageal Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 3
- 主要终点
- Preventable locoregional recurrence by the use of PET/CT-based treatment planning, instead of CT-based
研究概览
简要总结
The RESPECT study is intended to prospectively assess the impact of PET/CT on the delineation of target volumes and to estimate the proportion of recurrences that could possibly be prevented by the use of PET/CT-based target volume, instead of CT-based. Patients will recieve radiotherapy using CT-based planning, but a PET/CT-based treatment plan will also be made. CT-based and PET/CT-based target volumes will be compared after treatment has been completed. If a locoregional recurrence takes place, the localisation will be compared to the CT-based and PET/CT based clinical target volumes (CTVs). If the local recurrence is located outside the CT-CTV but inside the PET/CT-CTV, the recurrence could possibly have been prevented with PET/CT-based radiotherapy.
详细描述
This is a prospective cohort study testing the hypothesis that in a proportion of patients, locoregional recurrence, observed at 6, 12 or 18 months after treatment, can be prevented if PET/CT-based treatment planning was used instead of CT-based treatment planning alone.
Patients eligible for the study will undergo definitive radiotherapy with or without concomitant chemotherapy with planning-CT based target volumes, either or not followed by surgery.
A planning-PET/CT will be made for research purposes only, and will be blinded for the treating physicians. This planning-PET/CT will not be used for actual treatment planning.
In case of neoadjuvant chemoradiation the response on this therapy will be analysed at pathologic evaluation of the esophageal specimen.
Routine follow up will be carried out every 6 months, using CT. In case of no locoregional recurrence and/or metastases, patients will be followed up to 18 months for study evaluation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven adenocarcinoma or squamous cell carcinoma of the esophagus or GEJ
- •Locally curable disease without distant metastases (M1b is excluded) (TNM clinical classification UICC 7th edition)
- •Planned for high dose radiotherapy with or without chemotherapy with or without surgery
- •Age ≥ 18 years;
- •WHO performance status 0-2
- •informed consent must be given according to ICH/EU GCP, and national/local regulations
排除标准
- •previous or concurrent malignancies (except basal cell carcinoma of the skin or in situ carcinoma of the cervix or superficial bladder cancer (pTa)) in the past five years
- •Previous treatment
- •Evidence of serious active infections
- •any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
结局指标
主要结局
Preventable locoregional recurrence by the use of PET/CT-based treatment planning, instead of CT-based
时间窗: 18 months
Proportion of patients with a locoregional recurrence, observed at 6, 12 or 18 months after treatment, can the recurrence be considered as possibly preventable if PET/CT-based treatment planning was used instead of CT-based treatment planning alone (located outside the CT-based CTV, but inside the PET/CT-based CTV)
次要结局
- Differences in dose distribution to OAR for CT and PET/CT-based treatment plans(6 months)
- Percentage of patients who develop distant metastases after treatment(18 months)
- Differences in GTV, CTV and PTV for CT-based and PET/CT-based treatment planning(6 months)
- Cost-effectivity analyses(24 months)
研究者
Johannes A. Langendijk
M.D., Ph.D.
University Medical Center Groningen